What is Lithera?
Lithera operates at the intersection of advanced biotechnology and therapeutic innovation. The company is dedicated to developing novel solutions that address unmet medical needs, leveraging a robust research framework to drive scientific breakthroughs. By maintaining a focus on high-value diagnostic and pharmaceutical applications, Lithera has established itself as a key player in the healthcare sector. Its market position is bolstered by a commitment to rigorous clinical validation and a strategic approach to intellectual property, ensuring that its product offerings remain at the forefront of medical technology. The company's growth trajectory is supported by a history of disciplined capital allocation and a clear vision for transforming patient care through molecular-level interventions.
How much funding has Lithera raised?
Lithera has raised a total of $20.6M across 1 funding round:
Series C
$20.6M
Series C (2012): $20.6M with participation from AMOREPACIFIC US, Alta Partners, RusnanoMedInvest, and Domain Associates
Key Investors in Lithera
AMOREPACIFIC US
Amorepacific is a South Korean beauty and cosmetics company, focusing on skincare, haircare, and makeup products.
Alta Partners
Alta Partners is a prominent venture capital firm specializing in healthcare and life sciences, dedicated to supporting entrepreneurs in building impactful companies since 1996.
Domain Associates
DomainVC is an investment advisory firm established in 1985, specializing in biotech investments with a track record of managing multiple venture capital funds.
What's next for Lithera?
Looking ahead, the strategic deployment of the $20.6M will likely focus on scaling clinical trial operations and enhancing the company's proprietary technology platform. As Lithera transitions into its next phase of development, the focus will shift toward commercialization readiness and the potential for strategic partnerships that can amplify its market reach. The backing from established venture capital firms provides a stable foundation for these initiatives, allowing the leadership team to prioritize long-term value creation over short-term volatility. Investors will be closely monitoring the company's progress in achieving key regulatory milestones, which remain critical for sustaining its current growth momentum and securing future financing rounds.
See full Lithera company page
